Regenxbio doses first patient in Phase IIb/III NAAVIGATE trial of sura-vec for diabetic retinopathy, triggers $100 million AbbVie milestone

REGENXBIO, Inc.
AbbVie, Inc.

REGENXBIO, Inc.

RGNX

0.00

AbbVie, Inc.

ABBV

0.00
  • Regenxbio dosed the first patient in the Phase IIb/III NAAVIGATE trial of surabgene lomparvovec for diabetic retinopathy.
  • AbbVie will pay a USD 100 million milestone tied to the trial start, strengthening near-term cash inflow and partnership execution.
  • The study tests whether a one-time gene therapy can slow disease progression, aiming to reduce reliance on repeated retinal interventions.
  • Long-term data from the diabetic retinopathy program will be presented at the American Society of Retina Specialists meeting in July 2026.
  • Five-year wet AMD follow-up data will also be presented at that meeting, with pivotal subretinal trial topline results expected in Q4 2026.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Regenxbio Inc. published the original content used to generate this news brief via PR Newswire (Ref. ID: 202606290705PR_NEWS_USPR_____PH93698) on June 29, 2026, and is solely responsible for the information contained therein.

This page is machine-translated. Sahm tries to improve but does not guarantee the accuracy and reliability of the translation, and will not be liable for any loss or damage caused by any inaccuracy or omission of the translation. *Disclaimer: The above content only represents the author's personal position and opinion and does not represent any position of Sahm Capital Financial Company and Sahm cannot confirm the authenticity, accuracy, and originality of the above content. Investors should consider the risks of investment products in light of their circumstances before making any investment decisions. When necessary, please consult a professional investment advisor. Sahm does not provide any investment advice, nor does it make any commitments and guarantees.